<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The most commonly prescribed class of medications in the United States for <z:hpo ids='HP_0011010'>chronic</z:hpo> severe pain is <z:chebi fb="0" ids="35482">opioid analgesics</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Due to their low cost and widespread availability, the synthetic opioids are popular choices among clinicians and patients </plain></SENT>
<SENT sid="2" pm="."><plain>However, there is an increasingly recognized risk of QT prolongation with several drugs in this class, and recently <z:chebi fb="0" ids="8497">propoxyphene</z:chebi> (Darvon) was withdrawn from the market by the Food and Drug Administration (FDA) due to, in part, the risk of QT prolongation and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> Updated Epidemiological Review of <z:chebi fb="0" ids="8497">Propoxyphene</z:chebi> Safety </plain></SENT>
<SENT sid="3" pm="."><plain>[FDA Alert] </plain></SENT>
<SENT sid="4" pm="."><plain>Rockville, MD: U.S </plain></SENT>
<SENT sid="5" pm="."><plain>Food and Drug Administration; 2010 </plain></SENT>
<SENT sid="6" pm="."><plain>Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM234383.pdf on 5 May 2012  </plain></SENT>
</text></document>